Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00934180 · ClinicalTrials.gov registry record · Phase 1
Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00934180: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT00934180 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00934180, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The objective of this study was to compare the relative bioavailability of the test formulation of Ondansetron HCl with the already marketed reference formulation Zofran ODT under fasting conditions in healthy, non-smoking adult subjects.
Interventions
- DRUG Ondansetron
- DRUG Zofran®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2002-12 |
| Est. Completion | 2002-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00934180
The ClinicalTrials.gov registry entry for NCT00934180 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ondansetron is the first listed.
NCT00934180 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00934180 about?
NCT00934180 is a clinical study titled "Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions". The objective of this study was to compare the relative bioavailability of the test formulation of Ondansetron HCl with the already marketed reference formulation Zofran ODT under fasting conditions in healthy, non-smoking adult subjects.
What is the current status of trial NCT00934180?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2002-12. Estimated completion is 2002-12.
What interventions are being tested in trial NCT00934180?
The interventions under investigation include: Ondansetron (DRUG), Zofran® (DRUG).
Who is sponsoring clinical trial NCT00934180?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.